Recombinant CD19 (Tafasitamab Biosimilar) antibody

Catalog No. ABIN7598017

The Humanized Chimeric anti-CD19 (Tafasitamab Biosimilar) antibody is suitable to detect CD19 (Tafasitamab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD19 (Tafasitamab Biosimilar) antibody (ABIN7598017)

Target: CD19 (Tafasitamab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Chimeric

Conjugate: This CD19 (Tafasitamab Biosimilar) antibody is un-conjugated

Application: Please inquire

Grade: Research Grade

Product Details anti-CD19 (Tafasitamab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Research Grade Tafasitamab Biosimilar Antibody

Specificity: CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Purification: Protein A or G purified from cell culture supernatant.

Purity: >95 % by SDS-PAGE.

Isotype: IgG1 IgG2 mix

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 6.03 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Expiry Date: 12 months

Target Details for CD19 (Tafasitamab Biosimilar)

Target: CD19 (Tafasitamab Biosimilar)

Alternative Name: Tafasitamab Biosimilar

Target Type: Biosimilar

Background: CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

UniProt: P15391

CAS-No: 1422527-84-1